Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer
Jonathan Wilkie(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Craig Vargo(University of Pisa), Robert Wesolowski(The Ohio State University Wexner Medical Center), Nicole Williams(The Ohio State University), Daniel G. Stover(Harvard University), Jeffrey VanDeusen(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Raquel E. Reinbolt(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Junan Li(University of Shanghai for Science and Technology), Sagar Sardesai(The Ohio State University), Anne M. Noonan(The Ohio State University), Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), M. Alexandra Schickli(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 47
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
|Nature|2016|629
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells
|Proceedings of the National Academy of Sciences|2017|373
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296